Biovica International AB (publ) (STO:BIOVIC.B)
Sweden · Delayed Price · Currency is SEK 0.3330
0.00 (0.00%)
May 21, 2026, 10:21 AM CET
Biovica International AB Company Description
Biovica International AB (publ), a biotechnology company, develops and commercializes blood-based biomarker assays that enhance the monitoring and predicting of cancer therapies in Sweden and internationally.
It primarily focuses on breast cancer. The company develops DiviTum, a biomarker assay that measures the activity of the enzyme thymidine kinase-1 in blood serum or cell cultures.
It serves cancer institutes, pharmaceutical companies, and collaborative groups. The company was incorporated in 2008 and is headquartered in Uppsala, Sweden.
Biovica International AB (publ)
| Country | Sweden |
| Founded | 2008 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 24 |
| CEO | Anders Rylander |
Contact Details
Address: Dag Hammarskjölds väg 54B Uppsala, Uppsala County Uppsala County Sweden | |
| Phone | 46 1 84 44 48 30 |
Stock Details
| Ticker Symbol | BIOVIC.B |
| Exchange | Nasdaq Stockholm |
| Fiscal Year | May - April |
| Reporting Currency | SEK |
| ISIN Number | SE0008613731 |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| Anders Rylander | President, Chief Executive Officer and Director |
| Anders Moren | Chief Financial Officer |
| Hanna Ritzén | Senior Vice President of Global Marketing and Business Development |
| Henrik Winther D.V.M., Ph.D. | Senior Vice President of Business Development |
| Hector Tamburini | Head of US Laboratory Operations, Regulatory and Quality |